Merck KGaA Expands German Production Facility for Allergopharma Unit - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck KGaA Expands German Production Facility for Allergopharma Unit


Merck KGaA broke ground on a new production facility for its Allergopharma unit in Reinbek near Hamburg, the company announced in a press release. The new facility is estimated to cost nearly € 40 million ($55 million) and will be constructed on the current Allergopharma premises, with completion scheduled for 2016.

The facility will manufacture products for the diagnosis and treatment of type 1 allergies such as hay fever or allergic asthma under ultrapure, sterile conditions. The expansion will be used, among other things, to serve new markets, such as China. The new building will have a surface area of more than 6,000 square meters.

The market for allergy therapies (excluding symptomatic treatments) is showing strong global growth generated by an increasing number of people with allergies and by increasing use of specific immunotherapies in many emerging markets. Global growth is estimated to be between 5% and 10% per year, according to the press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here